Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 167 results for chronic heart failure

  1. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

  2. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

  3. Ivabradine for treating chronic heart failure (TA267)

    Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.

  4. Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure

    In development [GID-NG10405] Expected publication date: TBC

  5. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

  6. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

  7. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

  8. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

  9. Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

  10. Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) (TA731)

    NICE is unable to make a recommendation on vericiguat (Verquvo) for treating chronic heart failure with reduced ejection fraction in adults because Bayer did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA731

  11. Acute heart failure: diagnosis and management (CG187)

    This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.

  12. Optimising Medication in patients with Chronic Heart Failure

    management of patients with heart failure (HF) in primary care. Using a virtual clinic model, 872 patients on GP...

  13. Delivering Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF) in Wirral

    patients with chronic heart failure. Cardiovascular rehabilitation is indicated as an effective treatment option for patients with...

  14. How we used a World Café as a springboard to support heart failure teams in Kent, Surrey and Sussex to implement the new NICE guidelines for chronic heart failure.

    database Organisation: Kent Surrey and Sussex Heart Failure Collaborative Published date: June 2019

  15. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.